S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Shocking Bank Secret of the Ultra-Rich (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
The #1 Energy Passive Income Investment for 2023 (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
The Retirement of Your Dreams Awaits You… (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

$16.65
-0.20 (-1.19%)
(As of 02/28/2024 ET)
Today's Range
$16.11
$17.09
50-Day Range
$9.19
$19.97
52-Week Range
$5.12
$20.69
Volume
782,268 shs
Average Volume
716,048 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Edgewise Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.1% Upside
$24.00 Price Target
Short Interest
Bearish
8.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Edgewise Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Acquiring Shares
$5.10 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.16 out of 5 stars

Medical Sector

509th out of 958 stocks

Pharmaceutical Preparations Industry

241st out of 446 stocks


EWTX stock logo

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Stock Price History

EWTX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up to $17.37
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Edgewise Therapeutics: Q4 Earnings Insights
Edgewise Therapeutics Non-GAAP EPS of $0.47
Edgewise Therapeutics Inc (EWTX)
EWTX May 2024 30.000 call
See More Headlines
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
88
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$25.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+44.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-100,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.02 per share

Miscellaneous

Free Float
43,186,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
0.16
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Chairman
    Comp: $73k
  • Dr. Kevin Koch Ph.D. (Age 64)
    President, CEO & Director
    Comp: $913.1k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Co-Founder & Independent Director
    Comp: $40k
  • Dr. Alan J. Russell Ph.D. (Age 54)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $657.52k
  • Dr. Joanne M. Donovan M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $695.48k
  • Mr. R. Michael Carruthers (Age 66)
    Chief Financial Officer
    Comp: $386.01k
  • Mr. John R. Moore (Age 60)
    General Counsel
  • Dr. Behrad Derakhshan Ph.D. (Age 44)
    Chief Business Officer
    Comp: $575.53k
  • Dr. Marc Semigran M.D. (Age 67)
    Chief Development Officer














EWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price target for 2024?

3 analysts have issued 12 month price targets for Edgewise Therapeutics' shares. Their EWTX share price targets range from $23.00 to $25.00. On average, they predict the company's stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2024?

Edgewise Therapeutics' stock was trading at $10.94 on January 1st, 2024. Since then, EWTX shares have increased by 52.2% and is now trading at $16.65.
View the best growth stocks for 2024 here
.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EWTX earnings forecast
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05.

What ETFs hold Edgewise Therapeutics' stock?

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED) and iShares Neuroscience and Healthcare ETF (IBRN) and

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Frazier Life Sciences Management L.P. (4.20%), Vanguard Group Inc. (3.35%), Granahan Investment Management LLC (1.69%), Goldman Sachs Group Inc. (1.39%), Barclays PLC (1.23%) and Opaleye Management Inc. (1.10%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan C Fox, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EWTX) was last updated on 2/29/2024 by MarketBeat.com Staff